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Introduction: Whether pediatric patients with differentiated thyroid carcinoma (DTC) are 
at risk of developing treatment-related adverse effects on cardiac function is unknown. We 
therefore studied in long-term survivors of pediatric DTC the prevalence of cardiac 
dysfunction and atrial fibrillation (AF) in relation to treatment variables, and the 
association between cardiac dysfunction and plasma biomarkers.  
Patients and methods: In this nationwide prospective multicenter study, cardiac 
assessments were performed in 66 adult survivors of pediatric DTC (age at diagnosis ≤18 
years and follow-up ≥5 years after diagnosis) treated in The Netherlands between 1970 
and 2009. Assessment included echocardiography, plasma biomarkers (N-Terminal pro-
brain natriuretic peptide, high-sensitive Troponin-T, galectin-3), and 24-hour Holter 
electrocardiography. Echocardiographic measurements were compared with retrospective 
data of 66 sex- and age-matched unaffected Dutch controls. Diastolic dysfunction was 
defined as an early diastolic septal and/or lateral tissue velocity (e’). 
Results: The survivors (86.4% women) had at DTC diagnosis a median age of 16 years. 
Median follow-up was 17 years. Left ventricular ejection fraction <50% was found in one 
survivor, and median global longitudinal systolic strain was near normal. Diastolic 
dysfunction was present in 14 asymptomatic survivors (21.2%). Overall, diastolic function 
of survivors was lower compared to controls (e’mean 14.5 versus 15.8 cm/s, P = 0.006). 
Older attained age and higher waist circumference were associated with decreased 
diastolic function, whereas TSH levels and cumulative administered radioiodine dose were 
not. In survivors, biomarkers were not associated with diastolic dysfunction; AF was not 
observed.  
Conclusion: While systolic function is unaffected, diastolic dysfunction is frequently 






















































































































































































































































































































































Pediatric differentiated thyroid carcinoma (DTC), which comprises papillary (PTC) and 
follicular thyroid carcinoma (FTC), has an excellent prognosis with 15-year survival rates 
exceeding 95% (1). The initial treatment in children generally consists of a (near) total 
thyroidectomy, followed by ablation therapy with radioiodine (131-I), although nowadays 
the latter often depends on risk stratification (2-3). TSH suppressive therapy with thyroid 
hormone has for decades been administered during follow-up to diminish the risk of 
recurrent disease. However, its use is currently reduced in patients without evidence of 
disease (4-6). Long-term TSH suppressive therapy leads to subclinical hyperthyroidism. 
Possible harmful late effects of long-term subclinical hyperthyroidism on cardiac function 
are increasingly being recognized (7-8). Subtle LV systolic dysfunction has been shown in 
adult patients with DTC on TSH suppressive therapy (9-10).  Furthermore, diastolic 
dysfunction has been reported in adult patients with DTC after long-term TSH suppression 
(9). In addition to echocardiographic changes, plasma cardiac biomarkers may indicate 
(subclinical) cardiac dysfunction and may contribute to understanding the mechanisms 
underlying cardiac damage. An increased risk of atrial fibrillation (AF) has been described 
in adult patients with DTC. A higher cumulative radioiodine dose was associated with 
increased AF risk, while TSH levels were not (11).  
Late cardiac effects of treatment in survivors of pediatric DTC have yet to be 
assessed. Detailed insight into possible late adverse events is needed to improve 
treatment guidelines and follow-up strategies in the still growing population of survivors of 
pediatric DTC. We therefore studied: 1) the prevalence of cardiac dysfunction in long-term 
survivors of pediatric DTC in relation to treatment variables including TSH level during 
follow-up, 2) the association between cardiac dysfunction and plasma biomarkers (N-
Terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitive Troponin-T (hs-





















































































































































































































































































































































Patients and methods 
Study design and population 
This study is part of a nationwide Dutch study on pediatric DTC, previously described in 
detail (12). For this study on cardiac endpoints, subjects who met the following inclusion 
criteria were invited to participate: (a) PTC or FTC diagnosed between January 1970 and 
August 2009; (b) age at diagnosis ≤18 years; (c) age at cardiac evaluation ≥18 years; (d) 
treatment in The Netherlands; and (e) surviving at least 5 years after diagnosis. Exclusion 
criteria were a history of other malignant disease prior to DTC diagnosis, pregnancy at time 
of evaluation, and thyroid hormone withdrawal or recombinant human TSH stimulation <3 
months before evaluation. Reference data for echocardiography were derived from the 
recommendations of the American Society of Echocardiography (13-15). 
Echocardiographic measurements were also compared to those of an external control 
group, derived from another Dutch cohort study that included unaffected siblings of 
childhood-cancer survivors. Details on the methodology of this control group are described 
elsewhere (16). Each survivor was matched with a control subject based on sex and, as 
best as possible, age at time of cardiac assessment. Details on the methodology of the 
control group are described elsewhere (16). The Institutional Review Board of the 
University Medical Center Groningen approved the study. Written informed consent was 
obtained from all subjects. Assessments of survivors were performed between November 
2012 and September 2014 and included medical history, a health and risk factor 
questionnaire, a physical examination, echocardiography and blood sampling. Assessments 
of controls were performed between August 2004 and April 2007.  
 
Clinical and cardiac examinations 
A single physician (MSKH) performed the physical examinations. Echocardiographic image 
acquisition was performed locally according to a pre-specified image acquisition protocol. 
Images were stored digitally in DICOM format for offline central analysis at the Groningen 
Imaging Core Laboratory on an EchoPac analysis system, software version BT12 (General 
Electric, Horton, Norway). Echocardiographic evaluation consisted of left ventricular (LV) 
dimensions and volumes. Where appropriate, results were indexed for body surface area. 



















































































































































































































































































































































Simpson’s biplane method of discs. When image quality was insufficient for reliable 
endocardial border definition, the LVEF was estimated (so called ‘eyeballing LVEF’). Systolic 
dysfunction was defined as a LVEF <50% (17). In addition, global longitudinal systolic strain 
(ε, GLSS), which is a sensitive tool to measure myocardial deformation, was evaluated as a 
measure for systolic LV function. GLSS measurements were performed by two experienced 
operators (YH and FB), independently of each other, using 2D speckle tracking technique. 
The mean of both GLSS measurements was taken for analysis. GLSS was measured at the 
apical two-chamber, four-chamber, and long-axis views and was derived from the average 
of 18 segmental peak systolic strain values, i.e. 6 segments for each apical view. If more 
than one segment could not be measured accurately, the longitudinal strain 
measurements were not included in the analysis. Strain measurements were available only 
for the survivors. Assessment of LV diastolic function consisted of transmitral inflow 
measurements (early and late mitral valve inflow, deceleration time and isovolumetric 
relaxation time), and early diastolic tissue velocities. Diastolic dysfunction was defined as 
an early diastolic septal and/or lateral tissue velocity (e’) less than 2 SD of mean age-
adjusted reference data (13). Early diastolic tissue velocities of the survivors were 
measured using pulsed-wave Tissue Doppler Imaging (PW-TDI), while in the control group 
color-coded TDI (CC-TDI) was used (16). E’ values were converted as follows: e’(PW-TDI) = 
1.25 + 1.17 * e’(CC-TDI) (18). E’mean was calculated as the mean of septal and lateral e’. 
Finally, right ventricular (RV) systolic function was assessed with tricuspid annular plane 
systolic excursion (TAPSE) among the survivors. The operator who performed the 
echocardiographic measurements in the survivors also performed these measurements in 
the control group. 
Electrocardiographic evaluation consisted of 24-hour Holter electrocardiography (ECG) 
monitoring using an ambulatory Seer Light Extend recorder. Analysis was performed 
centrally by a single certified analyst (JR) using MARS analysis software (General Electric). 
Operators were blinded for medical characteristics of the survivors for both 





















































































































































































































































































































































Laboratory measurements  
Fasting blood samples of the survivors were collected concomitantly with the cardiac 
assessments. The following biomarkers were selected: NT-proBNP, a sensitive marker to 
exclude heart failure, hs-Troponin-T, a marker of cardiac damage, and galectin-3, a cardiac 
fibrosis marker (19-20). Measurements of cardiac biomarkers and TSH were performed at 
a central laboratory (UMC Groningen). TSH, NT-proBNP and hs-Troponin-T were measured 
in serum with an electrochemiluminescence immunoassay according to a sandwich 
principle on a Modular E170 immunoassay analyzer (Roche Diagnostics, Mannheim, 
Germany). Galectin-3 was measured in EDTA-plasma using a chemiluminescent sandwich 
based microparticle immunoassay on an Architect immunoassay analyzer (Fujirebio 
Diagnostics Inc, USA for Abbott Laboratories, Wiesbaden, Germany). The reference range 
for TSH was 0.5 to 4.0 mU/L. NT-proBNP ≥125 ng/mL, hs-Troponin ≥14 ng/L, and galectin-3 
≥17.8 ng/mL were considered clinically relevant.  
 
Study definitions  
Medical history, diagnosis, and treatment details were obtained from survivors’ medical 
records, as recently described in detail (12). Follow-up was calculated from the date of 
diagnosis until the date of the patient’s last known assessment. In all survivors, last 
assessment was the study visit with cardiac evaluation. All available historical TSH values 
were collected from the laboratory reports. Blood pressure was measured on both arms 
with subjects in sitting position in a quiet room at the time of the clinical visit. The mean of 
left and right arm measurements was used for analysis. Survivors were classified as having 
hypertension on the basis of a systolic blood pressure ≥140 mmHg, diastolic blood 
pressure ≥90 mmHg and/or the use of antihypertensive drugs. The waist circumference 
was measured both at the point of the smallest circumference of the abdomen and at the 
midpoint between the top of the iliac crest and the lower margin of the last palpable rib. 
For analysis, we took the mean of both measurements. All measurements were done by 
the same person (MKH). Diabetes mellitus was defined as fasting blood glucose level >7.0 
mmol/L and/or the use of glucose lowering medication. Hypercholesterolemia was defined 
as fasting cholesterol >6.5 mmol/L and/or use of lipid-lowering medication. History of 



















































































































































































































































































































































abdominal aorta aneurysm or cerebrovascular disease. History of AF was defined as 
documentation of this condition and/or prescription of antithrombotic drugs for this 
condition. Smoking status was obtained from a questionnaire completed by the survivor. 
Current AF was defined as AF present during 24-hour Holter ECG monitoring.  
 
Statistical analysis 
Data are presented as mean plus or minus standard deviation, geometric mean, or median 
and range. Groups were compared using Chi-square or Fisher’s exact tests (if conditions 
for Chi-square test were not met) in case of categorical variables. T-tests were performed 
for normally distributed continuous variables. Mann-Whitney U tests were performed for 
non-normally distributed continuous variables. Missing or unknown values were excluded 
from statistical testing. The TSH level for each year of follow-up was expressed as the 
geometric mean of all eligible TSH values during that year as previously described (12). The 
TSH value measured as part of this study was included in the calculation of the TSH level 
during the last year of follow-up. The TSH level during the entire follow-up was defined as 
the overall geometric mean of the calculated TSH levels per year (7,12). For the survivors, a 
univariate linear regression analysis of the association between each treatment modality 
with diastolic function, expressed as e’mean (the mean of septal and lateral e’), was 
succeeded by a multivariate regression analysis. In this analysis, we entered the variables 
of which we considered the associations with cardiac outcome measures to be biologically 
plausible and/or the variables which were associated (P <0.10) with diastolic function in 
univariate analyses. The model was subsequently reduced to the variables remaining 
significant in multivariate analysis (P <0.05). All tests were two sided. A P value of <0.05 
was considered statistically significant. IBM SPSS Statistics version 22 for Windows (IBM, 
Armonk, NY, USA) was used for statistical analyses.  
 
Results  
Characteristics of survivors and controls 
As shown in the study flowchart (Figure 1), 74 of the 105 survivors of pediatric DTC 
included in our previous study were eligible for participation in the present study. Of this 



















































































































































































































































































































































65 of them also underwent a 24-hour Holter ECG. Cancer-related characteristics are 
provided in Table 1. Median follow-up was 17 years (range 5 to 43 years). Most survivors 
had a history of PTC (83.3%); the remaining 16.7% had FTC. All survivors had undergone 
total thyroidectomy and 64 (97.0%) of them received radioiodine as ablation therapy 
and/or during follow-up. Median cumulative radioiodine activity administered during 
initial treatment and follow-up was 5.81 GBq (1.22 to 35.15 GBq). Of all survivors, both 
historical TSH values and TSH levels at time of cardiac evaluation were available for 
analysis. Median (geometric mean) TSH level during follow-up was 0.17 mU/L (range 0.02 
to 2.84 mU/L). TSH was suppressed to below 0.10 mU/L during the entire follow-up in 21 
survivors (31.8%). Median TSH at evaluation was 0.25 mU/L (range 0.01 to 14.6 mU/L). As 
shown in Table 2, the majority of survivors (86.4%) were female. Median age at cardiac 
evaluation of the survivors was 33 years (range 19 to 60 years), whereas the controls were 
aged 28 years (range 19 to 51 years) at evaluation (P = 0.027). Heart rate was significantly 
lower in survivors as compared to controls (P = 0.003). Survivors had a significantly higher 
fasting glucose (mean 5.0 vs. 4.5 mmol/L, P <0.001). However, none of the survivors or 
controls had diabetes mellitus. Two (3.0%) survivors vs. no controls had 
hypercholesterolemia. Hypertension was present in 9 (13.9%) survivors and 4 (6.1%) 
controls (P = 0.144). Finally, survivors were more often non-smokers as compared to 
controls (P = 0.017). 
 
Echocardiography 
Echocardiographic results are presented in Table 3. LV mass index and left atrial volume 
index (LAVI) were comparable in survivors and controls. Regarding LV systolic function, 
median LVEF of survivors and controls was 58.8% (range 48.0 to 73.0%) and 60.0% (range 
44.0 to 65.0%), respectively. In 11 survivors (16.7%) an eyeballing (estimated) LVEF was 
determined. One survivor had a LVEF <50%, while 5 controls had a LVEF <50% (P = 0.109). 
Using sex-specific reference values from the American Society of Echocardiography, one 
(11.1%) male survivor and one male control had a LVEF <52% (P = 1.000), and 6 (10.5%) 
female survivors and 13 (23.6%, 2 missing) female controls had a LVEF <54% (P = 0.065) 
(14). GLSS was available for 19 survivors. Median GLSS was -19.6% (range -24.2 to -17.6%). 



















































































































































































































































































































































software used in this study. Two survivors (10.5%) had a GLSS >-18%, namely a GLSS of -
17.6% and -17.7%, respectively, suggesting (near) normal systolic function in the survivors 
(14). Median TAPSE, which represents a measure of RV systolic function, was 25.0 mm 
(range 17.0 to 33.7 mm) (14). TAPSE values suggestive of RV dysfunction (i.e. <17.0 mm) 
were not observed.   
Diastolic dysfunction (using a strict definition) was present in 14 survivors (21.2%; median 
follow-up 21.4 years (range 6.8- to 42.9 years)), when compared with reference values 
from the literature (13). To verify this finding in the Dutch situation, we compared the 
diastolic function of the survivors with that of the controls (Table 3). In the control group 
(n = 66), we found diastolic dysfunction in 10.6% of the participants (versus 21.2% of the 
survivors, P = 0.096).  Echocardiographic measurements are depicted in Table 3. Both 
septal and lateral e’ were decreased compared to controls (P = 0.005 and P = 0.011, 
respectively), which confirms decreased diastolic function compared to controls. Early and 
late mitral valve inflow velocities were also lower in survivors compared to controls (both 
P <0.001). Seven survivors and one control had a LAVI >34 ml/m2, however, especially in 
many controls LAVI was lacking (Table 3). 
As shown in Table 4 and Supplemental Table 1, the following variables were associated 
with diastolic function (e’mean) among the survivors of pediatric DTC in univariate 
analysis, and were eligible for multivariate analysis: attained age at evaluation, fasting 
glucose, cholesterol, diastolic blood pressure and waist circumference. TSH and cumulative 
radioiodine activity were not associated with diastolic function. Sex was added to the 
adjusted model. In the final adjusted model increasing attained age and waist 
circumference were associated with decreased diastolic function (β coefficient -0.134, 95% 
CI -0.198 to -0.071, P <0.001 and β coefficient -0.091, 95% CI -0.136 to -0.046, P <0.001, 
respectively). A subanalysis showed no difference in the prevalence of diastolic 
dysfunction in survivors with a TSH <0.4 mU/L during follow-up (10 out of 53 survivors, 
18.9%) vs. survivors with a TSH ≥0.4 mU/L during follow-up (4 out of 13 survivors, 30.8%) 






















































































































































































































































































































































Plasma levels of NT-proBNP, hs-Troponin-T and galectin-3 did not differ between survivors 
with and without diastolic dysfunction (Table 5). The number of survivors with a NT-
proBNP >125 ng/L or Galectin-3 >17.8 ng/mL also did not differ between survivors with 
and without diastolic dysfunction.  
 
24-hour Holter electrocardiography 
24-hour Holter ECGs of 65 (98.5%) survivors were available for analysis. All survivors 
showed sinus rhythm; AF was not observed.   
 
Discussion 
This is the first nationwide study on late cardiac effects in survivors of pediatric DTC, 
showing frequent diastolic dysfunction in 21.2% of asymptomatic survivors after a median 
follow-up of 17 years, when compared to reference values from the literature and to a 
matched Dutch control group (13,16). As diastolic function declines with age, our findings 
may suggest early cardiac aging in survivors of pediatric DTC (15). This is important, as 
diastolic dysfunction may be the first manifestation of more overt heart failure (17). We do 
believe that the fact that we did not find a statistically significant difference between 
survivors and controls with respect to prevalence of diastolic dysfunction (P = 0.096) might 
be due to the small numbers of studied subjects using a strict definition of diastolic 
dysfunction. Since we found significant differences when comparing the mitral valve inflow 
and diastolic tissue velocities, we conclude that the high percentage of diastolic 
dysfunction in survivors and the significant differences in echocardiographic 
measurements between survivors and controls might be clinically relevant. 
In our cohort, increasing attained age and waist circumference were associated 
with decreased diastolic function, which are established risk factors for diastolic 
dysfunction (17). We hypothesized that TSH would also be associated with diastolic 
dysfunction, as has been shown earlier by Smit et al. (9). Remarkably, this was not the 
case. A possible explanation for the different results may be related to the age of the 
survivors included in the studies. In our cohort, survivors were almost 17 years younger 



















































































































































































































































































































































suppression. The TSH baseline TSH and six months follow-up TSH values reported in the 
study of Smit et al. (<0.006 0.05 mU/l and 0.02 mU/l, respectively) (9) were lower than in 
our study (0.17 mU/l) (9). However, the definition of TSH suppression and the number of 
TSH values available to support the TSH suppression are quite different in both studies. In 
our study, we used all available TSH values, and it revealed that TSH was suppressed to 
below 0.10 mU/L only in one-third of the survivors during the entire follow-up. In contrast, 
in the study by Smit et al. the TSH value during yearly follow-up was used to confirm 
suppression. Thus, it is unclear whether the results of these two studies can be compared. 
Although it has been shown that the degree of TSH suppression is related to cardiovascular 
mortality, it may be that diastolic dysfunction is triggered by TSH suppression per se rather 
than the level of TSH suppression (7). Increasing attained age, which could also be 
interpreted as a measure for longer duration of TSH suppression, was associated with 
decreased diastolic function in our cohort. Smit et al. included patients with a mean 
duration of TSH suppressive therapy (TSH <0.4 mU/L) of 12 years (9). In our study, median 
follow-up was 17 years. However, the assumption that attained age is a measure for 
duration of TSH suppression should be interpreted with caution as factors like potential 
nonadherence and prescriber factors may have impacted actual duration of TSH 
suppression. Furthermore, in our cohort all survivors used only levothyroxine (T4) as 
thyroid hormone replacement. It has been shown in thyroidectomized rats on T4 that 
circulating T3 does not always reflect tissue T3 levels in the heart (21). Tissue T3 has been 
proposed to elicit adverse cardiovascular effects when elevated (22). Therefore, it remains 
questionable whether the plasma TSH level is an adequate measure for cardiac tissue 
hyperthyroidism. Recently, an association between higher free T4, but not TSH, and 
increased risk of sudden cardiac death was shown (23). Unfortunately, free T3 and T4 
levels during follow-up were not available for our study.  
Systolic function was assessed by measurement of the LVEF and GLSS. GLSS has 
been shown to be of great additional value in detecting subclinical myocardial changes in 
adult cancer survivors, changes which can precede LVEF decreases and overt heart failure 
(8,24).  In our cohort, systolic function was unaffected. In contrast to our findings, 
Abdulrahman et al. observed subtle systolic dysfunction using 2D speckle tracking 



















































































































































































































































































































































significantly lower LVEF compared to controls, although LVEF remained within the 
reference range (9). The explanation for the different results may be, again, that survivors 
in our cohort were younger than those in the other studies.   
Our finding of frequent diastolic dysfunction is in line with findings in other cohorts 
of long-term childhood cancer survivors (16,25-29). In those cohorts, systolic dysfunction 
has also been described (16,25-29). However, as survivors in those cohorts were treated 
with anthracyclines and/or mediastinal radiotherapy, the mechanisms that trigger cardiac 
dysfunction may differ. 
The question remains which factors explain the diastolic dysfunction found in our 
cohort. The development of diastolic dysfunction is a multifactorial process (17). Patients 
have their individual cardiovascular risk factors, which make them more or less inclined to 
develop diastolic dysfunction. We hypothesize that thyroid cancer treatment causes more 
rapid cardiac function deterioration by superposing the traditional risk factors also 
associated with decreased diastolic function in our cohort. Additionally, a subtle 
hyperdynamic state caused by the subclinical hyperthyroidism may contribute to the 
development of diastolic dysfunction. This hyperdynamic state arises as thyroid hormones 
stimulate the β-adrenergic signaling, leading to positive chronotropic and inotropic effects 
(30).   
This study did not find an association between plasma levels of NT-proBNP, hs-
Troponin-T and galectin-3 and diastolic dysfunction. An explanation for this may be that 
the diastolic dysfunction in our cohort was subclinical and therefore too mild to induce 
changes in plasma biomarkers. This implies that by measuring cardiac biomarkers alone, 
survivors with asymptomatic diastolic dysfunction could not be identified in our cohort.  
AF was not observed using 24-hour ECG monitoring. In a cohort of adult survivors 
of DTC, an increased AF risk was described, independent of AF risk factors (11). However, 
in our study, survivors are significantly younger, and therefore had fewer risk factors for 
AF. 
The strength of this study is that it is the first study of cardiac function in long-term 
survivors of pediatric DTC, and includes data on cardiovascular risk factors available for all 
subjects. Furthermore, detailed data on tumor and treatment characteristics (including 



















































































































































































































































































































































Assessment of GLSS was included in cardiac evaluation. Moreover, cardiac measurements 
were performed centrally, and interobserver variation was minimized, as the operator who 
performed all echocardiographic measurements in the survivors also performed these 
measurements in the control group (16).  
Some limitations require comment. First, due to small patient numbers this study 
may suffer from a lack of power and therefore mild cardiac effects may be missed. Second, 
due to a different age distribution in both cohorts, the controls were slightly younger than 
the survivors despite matching and therefore the diastolic dysfunction cannot exactly be 
dissociated from the effects of ageing per se. However, as reference data of the American 
Society of Echocardiography are adjusted per 20 years, in our opinion, a less than 5 years 
age difference is acceptable (13). Third, control data were collected between 2004 and 
2007, whereas the data of the survivors were collected between 2012 and 2014 using 
different echo techniques, which may introduce bias. However, both methods are strongly 
correlated and therefore important differences in diastolic function due to the different 
echo techniques are not expected (18). Fourth, biomarkers were available only for the 
survivors. Finally, various TSH assays were used. However, we expect that the assay 
differences had limited influence on the results because the lower limits of the reference 
ranges remained more or less stable. As discussed earlier, free T3 and T4 levels during 
follow-up were not available for our study.  
In conclusion, diastolic dysfunction was observed in 21.2% of long-term survivors of 
pediatric DTC using a strict definition of diastolic dysfunction, whereas systolic function 
remained unaffected in the majority of survivors. Increasing attained age and waist 
circumference were associated with decreased diastolic function, while TSH levels during 
follow-up were not. Since diastolic dysfunction is more common in the elderly, our findings 
suggest early cardiac aging in survivors of pediatric DTC. Indeed, the median age of 
survivors with diastolic dysfunction was only 38 years. Although diastolic dysfunction was 
subclinical, it is clinically relevant as it may be the first manifestation of more overt heart 
failure (17). Therefore, assessment and treatment of cardiovascular risk factors may 
require additional attention in this patient group as is already the case in other cancer 
survivors. An echocardiography might be easy accessible in the follow-up of survivors of 



















































































































































































































































































































































dysfunction in survivors of pediatric DTC our data need to be confirmed in other cohorts 
survivors data from other cohorts are needed. Moreover, follow-up studies are necessary 
to explore the longitudinal course of the diastolic dysfunction and potential intervention 
targets in survivors of pediatric DTC and to unravel pathophysiological mechanisms. 
Finally, it should be emphasized that cardiology follow-up together with regular 
communication between endocrinologists and cardiologists is required and that staging is 
mandatory before long-term, sometimes life-long, suppression treatment is implemented. 
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Table 1. Cancer-related characteristics of survivors of pediatric DTC
Variable Survivors (n = 66) 
Age at diagnosis (years)  
 Median (range) 15.9 (7.9-18.9)
Follow-up (years)  
 Median (range) 17 (5-43)
Histology, no. (%)  
 Papillary 55 (83.3)
 Follicular 11 (16.7)
TNM stage, no. (%)  
 T 
  T1-T2 41 (62.1)
  T3-T4 13 (19.7)
  Tx 12 (18.2)
 N 
  N0 31 (47.0)
  N1a-N1b 30 (45.5)




















































































































































































































































































































































  M0 56 (84.8)
  M1 (lung) 5 (7.5)
  Mx 5 (7.5)
Total thyroidectomy, no. (%) 66 (100)
Radioiodine ablation, no. (%)a 58 (87.9)
Cumulative radioiodine activity (GBq)b  
 Median (range) 5.81 (1.22-35.15)
TSH level during follow-up (geometric 
mean) (mU/l) 
 
 Median (range) 0.17 (0.02-2.84)
Cervical radiation, no. (%)c 1 (1.5)
Chemotherapy or tyrosine kinase 
inhibitors 
0 (0.0)
Current use of levothyroxine 66 (100)
Current use of liothyronine 0 (0.0)
Clinical outcome, no. (%)   
 Remission 55 (83.3)
 Recurrence 7 (10.6)
 Persistent disease 4 (6.1)



















































































































































































































































































































































aRadioiodine (131-I) administration within 6 months after initial treatment. 
bAdministered 131-I activity during initial treatment and follow-up; activity 
unknown in 1 survivor, and 2 survivors did not receive 131-I treatment. Therefore, 
n = 63 instead of n = 66. cOne survivor received radiotherapy directed to the neck 




















































































































































































































































































































































Table 2. General characteristics and cardiovascular risk factors of survivors of 
pediatric DTC and controls 
Variable Survivors (n = 66) Controls (n = 66) P value
Sex, no. (%)   
 Male 9 (13.6) 9 (13.6) 
-
 Female 57 (86.4) 57 (86.4) 
Age at cardiac assessment (years)   
 Median (range) 33 (19-60) 28 (19-51) 0.027
Heart rate (beats/min)    
 Mean ± SD 66.7 ± 9.6 72.5 ± 12.3 0.003
Body mass index (kg/m2)    




Body surface area (m2)   
 Median (range) 1.8 (1.6-2.4) 1.8 (1.6-2.2) 0.920
Fasting glucose (mmol/L)a  
 Mean  SD 5.0 ± 0.51 4.5 ± 0.46 <0.001
Cholesterol (mmol/L)   
 Median (range) 4.6 (3.2-7.1) 4.5 (2.4-6.2) 0.792



















































































































































































































































































































































 No 42 (63.6) 32 (48.5) 
0.017 Current  9 (13.6) 23 (34.8) 
 Past  15 (22.7) 11 (16.7) 
Systolic blood pressure (mmHg)b  
 Median (range) 119 (100-145) 115 (98-140) 0.258
Diastolic blood pressure (mmHg)b   
 Median (range) 75 (50-100) 76 (55-104) 0.792
Waist circumference (cm)  







History of cardiovascular disease, 
no. (%)  
0 (0.0) 1 (1.5) 1.000
History of atrial fibrillation, no. 
(%)  
0 (0.0) - - -
Abbreviation: DTC, differentiated thyroid carcinoma. 
aFasting blood glucose missing in 3 survivors and 3 controls. bIn one survivor blood 





















































































































































































































































































































































Table 3. Echocardiographic measurements of survivors of pediatric DTC and 
controls 
Variable Survivors (n = 66) Controls (n = 66) P 
value




Left ventricular end diastolic diameter 
(mm) 
48 (39-59) 46 (39-57) 
0.113
0
Left ventricular mass index (g)a 66 (43-106) 64 (45-107) 0.723
Left ventricular end systolic diameter 
(mm)  
32 (22-46) 31 (22-42) 0.094
Left atrial volume indexb 28.6 (12.1-45.8) 32.0 (18.9-34.9) 0.248
  
Systolic function, median (range)  
Left ventricular ejection fraction (%)c 58.8 (48.0-73.0) 60.0 (44.0-65.0) 0.619
  
Diastolic function, median (range)  
Early diastolic mitral valve inflow (m/s) 0.84 (0.44-1.23) 0.97 (0.62-1.46) 
<0.00
1
Late diastolic mitral valve inflow (m/s) 0.50 (0.31-0.93) 0.59 (0.33-1.06) 
<0.00
1



















































































































































































































































































































































inflow (ms) 5 329.4) 0 269.0) 
E/A ratio 1.6 (0.7-3.3) 1.7 (0.9-2.9) 0.924
Isovolumetric relaxation time (ms)d 79.6 (58.4-182.3) 79.5 (55.0-105.0) 0.407
E/e’ ratio 5.9 (3.7-13.6) 6.1 (4.0-9.8) 0.070
Early diastolic septal tissue velocity 
(cm/s) 
12.9 (5.2-19.9) 14.2 (9.2-19.2) 0.005
Early diastolic lateral tissue velocity 
(cm/s) 
16.4 (5.1-27.4) 18.1 (11.5-20.3) 0.011
Mean of septal and lateral early 
diastolic tissue velocity (cm/s) 
(e’mean), mean  SD 
14.5 ± 3.4 15.8 ± 1.77 0.006
Abbreviations: DTC, differentiated thyroid carcinoma; E/A ratio, ratio early diastolic 
mitral valve inflow to late diastolic mitral valve inflow; E/e’ ratio, ratio early 
diastolic mitral valve inflow to mean of septal and lateral early diastolic tissue 
velocity.  
aLeft ventricular mass calculated with Devereux formula. bLeft atrial volume index 
available for 56 survivors and 15 controls. cLeft ventricular ejection fraction could 
not be measured in 3 controls. dIVRT Isovolumetric relaxation time available for 55 




















































































































































































































































































































































Table 4. Unadjusted and adjusted linear regression models for diastolic function 
(e’mean) among survivors of pediatric DTC 
Variable  Coefficient βa 95% CI P 
value 
R2 
Unadjusted models     
1. Attained age 








0.114 -1.181 to 2.046 0.906 
0.00
0 
4. Cumulative radioiodine 
activity (GBq) 
0.075 -0.032 to 0.182 0.166 
0.03
0 
5. Fasting glucose 




-1.435 -2.369 to -0.501 0.003 
0.12
8 
7. Diastolic blood pressure 
-0.182 -0.257 to -0.106 <0.001 
0.26
4 
8. Waist circumference 
-0.131 -0.177 to -0.086 <0.001 
0.34
4 
9. Current smoking 
1.034 -1.330 to 3.398 0.386 
0.01
2 
   
Adjusted models      
1. Attained age 
-0.197 -0.261 to -0.134 <0.001 
0.39
2 



















































































































































































































































































































































2. Attained age 
-0.129 -0.204 to -0.053 0.001 
0.54
0 
 Sex -1.678 -3.602 to 0.247 0.086  
 Fasting glucose 0.427 -1.068 to 1.923 0.569  
 Cholesterol -0.664 -1.511 to 0.183 0.122  
 Diastolic blood pressure -0.015 -0.111 to 0.081 0.757  
 Waist circumference -0.085 -0.139 to -0.030 0.003  
3. Attained age 
-0.134 -0.198 to -0.071 <0.001 
0.48
8 
 Waist circumference -0.091 -0.136 to -0.046 <0.001  
Abbreviations: e’mean, diastolic function expressed as mean of septal and lateral early 
diastolic tissue velocity; DTC, differentiated thyroid carcinoma.  





























































































































































































































































































































































(n = 52) 
P value 
NT-proBNP (ng/L)  
 Median (range) 61.5 (7-162) 49.5 (<5-225) 0.616
NT-proBNP ≥125 ng/L, no. (%) 1 (7.1) 7 (13.5) 1.000
hs-Troponin-T (ng/L)  
 Median (range) <3 (<3-11) <3 (<3-8) 0.793
Galectin-3 (ng/mL)  
 Median (range) 12.7 (8.0-18.2) 11.9 (6.2-15.9) 0.128
Galectin-3 ≥17.8 ng/mL, no. (%) 1 (7.1) 0 (0.0) 0.212
Abbreviations: DTC, differentiated thyroid carcinoma; NT-proBNP, N-Terminal pro-brain 





















































































































































































































































































































































Figure Legends  
 
Figure 1. Study flow chart, showing final number of included survivors, reasons for non-
eligibility for the present study of subjects who participated in the nationwide project (12), 
and reasons for non-participation of eligible survivors. 



















































































































































































































































































































































a12 survivors aged <18 years at evaluation had a follow-up <5 years. They were registered 
as attained age <18 years. bOne survivor <18 years at evaluation had a malignant disease 
prior to DTC diagnosis. He was registered as malignant disease prior to DTC. cOne survivor 
was excluded because of supposed malignancy prior to DTC. She gave informed consent 
for medical chart evaluation as part of the nationwide study. When her medical charts 
were reviewed, it was found that she was irradiated to the neck because of a benign 






















































































































































































































































































































































Supplemental Table 1. Unadjusted and adjusted linear regression models for diastolic 
function (e’mean) among survivors of pediatric DTC 
Variable  Coefficient βa 95% CI P 
value 
R2 
Unadjusted model 1 
   
0.35
4 
Attained age -0.190 -0.254 to -0.126 <0.001  
     
Unadjusted model 2 
   
0.01
6 
Sex -1.245 -3.710 to 1.220 0.317  
     
Unadjusted model 3 
   
0.00
0 
TSH 0.114 -1.181 to 2.046 0.906  
     
Unadjusted model 4 
   
0.03
0 
Cumulative radioiodine activity 
(GBq) 
0.075 -0.032 to 0.182 0.166  
     
Unadjusted model 5 
   
0.07
9 
Fasting glucose -1.925 -3.614 to -0.237 0.026  
     
Unadjusted model 6 
   
0.12
8 



















































































































































































































































































































































     
Unadjusted model 7 
   
0.26
4 
Diastolic blood pressure -0.182 -0.257 to -0.106 <0.001  
     
Unadjusted model 8 
   
0.34
4 
Waist circumference -0.131 -0.177 to -0.086 <0.001  
     
Unadjusted model 9 
   
0.01
2 
Current smoking  1.034 -1.330 to 3.398 0.386  
     
Adjusted model 1 
   
0.39
2 
Attained age -0.197 -0.261 to -0.134 <0.001  
Sex -1.953 -3.920 to 0.014 0.052  
     
Adjusted model 2  
   
0.54
0 
Attained age -0.129 -0.204 to -0.053 0.001  
Sex -1.678 -3.602 to 0.247 0.086  
Fasting glucose 0.427 -1.068 to 1.923 0.569  
Cholesterol -0.664 -1.511 to 0.183 0.122  
Diastolic blood pressure -0.015 -0.111 to 0.081 0.757  
Waist circumference -0.085 -0.139 to -0.030 0.003  
   




















































































































































































































































































































































Attained age -0.117 -0.194 to -0.040 0.004  
Sex -12.600 -28.798 to 3.598 0.125  
Fasting glucose 0.514 -0.977 to 2.004 0.493  
Cholesterol -0.822 -1.695 to 0.050 0.064  
Diastolic blood pressure -0.024 -0.120 to 0.072 0.618  
Waist circumference -0.093 -0.148 to -0.037 0.001  
Interaction waist 
circumference*gender 
0.122 -0.058 to 0.303 0.179  
 
 
Supplemental Table 1 (continued)
Variable  Coefficient βa 95% CI P 
value 
R2
   
Adjusted model 4 
   
0.54
0 
Attained age -0.132 -0.204 to -0.061 <0.001  
Sex -1.698 -3.602 to 0.206 0.079  
Fasting glucose 0.480 -0.965 to 1.925 0.509  
Cholesterol -0.715 -1.488 to 0.057 0.069  
Waist circumference -0.089 -0.135 to -0.043 <0.001  
     
Adjusted model 5 
   
0.54
1 
Attained age -0.124 -0.190 to -0.059 <0.001  
Sex -1.698 -3.445 to 0.048 0.056  



















































































































































































































































































































































Waist circumference -0.086 -0.130 to -0.043 <0.001  
   
Adjusted model 6 
   
0.51
5 
Attained age -0.143 -0.206 to -0.080 <0.001  
Sex -1.632 -3.411 to 0.147 0.071  
Waist circumference -0.087 -0.131 to -0.043 <0.001  
     
Adjusted model 7 
   
0.51
5 
Attained age -0.142 -0.206 to -0.078 <0.001  
Sex -2.894 -15.740 to 9.953 0.654  
Waist circumference -0.089 -0.135 to -0.042 <0.001  
Interaction waist 
circumference*gender 
0.014 -0.131 to 0.160 0.843  
     
Adjusted model 8 (final model) 
   
0.48
8 
Attained age -0.134 -0.198 to -0,071 <0.001  
Waist circumference -0.091 -0.136 to -0.046 <0.001  
Abbreviations: e’mean, diastolic function expressed as mean of septal and lateral early 
diastolic tissue velocity; DTC, differentiated thyroid carcinoma.  
aUnstandardized coefficient β. 
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